The Food and Drug Administration granted breakthrough therapy designation to a treatment regimen of two investigational drugs for patients with chronic hepatitis C virus who did not respond to ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart and elebsiran, a combination therapy developed for chronic Hepatitis B in ...

November 1, 202310:05 AM UTCUpdated November 1, 2023 Sign up here. Exclusive rights to the therapy will fuel the expansion of GSK's own hepatitis B treatment, bepirovirsen, which is currently in ...

Alcohol use at any level, including alcohol use disorder (AUD), is not associated with decreased odds of a sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy for chronic ...